Crossover Trial of Exogenous Ketones on Cardiometabolic Endpoints in Heart Failure With Preserved Ejection Fraction
JACC: Heart Failure · 2025-12 · 13 (12) · 102435
DOI: 10.1016/j.jchf.2025.03.002 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift JACC: Heart Failure, 2025-12. Verfasst von Senthil Selvaraj und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Duke University Medical Center, Durham, North Ca…. Hauptthemen laut MEDLINE: Exercise Tolerance, Heart Failure, Ketones, Stroke Volume. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NIA NIH HHS.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: The etiology of exercise intolerance in heart failure with preserved ejection fraction (HFpEF) is multifactorial. Several contributing pathways may be improved by ketone ester (KE). OBJECTIVES: This study aims to determine whether KE improves exercise tolerance in HFpEF. METHODS: KETO-HFpEF (Ketogenic Exogenous Therapies in HFpEF) is a randomized, crossover, placebo-controlled trial of acute KE dosing in 20 symptomatic HFpEF participants. Coprimary endpoints include peak oxygen consumption (VO2) during incremental cardiopulmonary exercise testing and time to exhaustion during an additional constant-intensity exercise (75% peak workload) bout. RESULTS: The average age was 71 ± 8 years, 60% were women, and 65% were White. KE did not improve peak VO2 (KE: 10.4 ± 3.6 vs placebo: 10.5 ± 4.0 mL/kg/min; P = 0.75). At rest, heart rate, biventricular systolic function, and cardiac output (0.6 L/min [95% CI: 0.3-1.0 L/min]) were greater with KE vs placebo, whereas total peripheral resistance (-3.2 WU [95% CI: -5.2 to -1.2 WU]) and the arteriovenous oxygen content difference (-0.7 mL of O2/dL blood [95% CI: -1.2 to -0.2 mL]) were lower. These differences mostly disappeared during incremental exercise. KE did not improve exercise endurance during the constant-intensity protocol (9.7 ± 7.3 minutes vs 8.7 ± 4.4 minutes; P = 0.51). In 6 participants receiving 6,6-2H2-glucose infusions during constant-intensity exercise, plasma glucose appearance rate before and during exercise was lower with KE (-0.24 mg/kg/min; P < 0.001). During both exercise protocols, KE lowered: 1) respiratory exchange ratios, demonstrating decreased systemic carbohydrate use; 2) nonesterified fatty acids and glucose; and 3) estimated left ventricular filling pressures (E/e'). CONCLUSIONS: Despite robust ketosis, shifting substrate use away from carbohydrates, and decreasing estimated left ventricular filling pressures, acute KE supplementation did not improve peak VO2 or constant-intensity exercise in HFpEF. (Ketogenic Exogenous Therapies in HFpEF [KETO-HFpEF]; NCT04633460).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Duke University Medical Center, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Durham, North Caroli…
- Department of Biostatistics, Epidemiology, and Informatics, the Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Medicine and Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Nephrology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Children's Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania, USA.
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- NIA NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
- Doris Duke Charitable Foundation
- American Heart Association Inc
Zitieren
APA
Selvaraj, S., Karaj, A., Chirinos, J. A., Denney, N., Grosso, G., Fernando, M., Chambers, K., Demastus, C., Reddy, R., Langham, M., Kumar, D., Maynard, H., Pourmussa, B., Prenner, S. B., Cohen, J. B., Ischiropoulos, H., Rickels, M. R., Poole, D. C., Church, D. D., …, & Zamani, P. (2025). Crossover Trial of Exogenous Ketones on Cardiometabolic Endpoints in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 13(12), 102435. https://doi.org/10.1016/j.jchf.2025.03.002
Vancouver
Selvaraj S, Karaj A, Chirinos JA, Denney N, Grosso G, Fernando M, et al. Crossover Trial of Exogenous Ketones on Cardiometabolic Endpoints in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2025;13(12):102435. doi:10.1016/j.jchf.2025.03.002
BibTeX
@article{Selvaraj2025,
author = {Selvaraj, Senthil and Karaj, Antoneta and Chirinos, Julio A and Denney, Nicole and Grosso, Gabby and Fernando, Melissa and Chambers, Kishon and Demastus, Cassandra and Reddy, Ravinder and Langham, Michael and Kumar, Dushyant and Maynard, Hannah and Pourmussa, Bianca and Prenner, Stuart B and Cohen, Jordana B and Ischiropoulos, Harry and Rickels, Michael R and Poole, David C and Church, David D and Wolfe, Robert R and Kelly, Daniel P and Putt, Mary and Margulies, Kenneth B and Zamani, Payman},
title = {Crossover Trial of Exogenous Ketones on Cardiometabolic Endpoints in Heart Failure With Preserved Ejection Fraction},
journal = {JACC: Heart Failure},
year = {2025},
volume = {13},
number = {12},
pages = {102435},
doi = {10.1016/j.jchf.2025.03.002}
}
EUVIMED